May. 6 at 8:15 PM
$CSTL Q1 '26 Earnings Results & Recap
• Reported GAAP EPS of -
$0.49 up 45.56% YoY
• Reported revenue of
$83.68M down -4.90% YoY
• Castle Biosciences is raising its 2026 total revenue guidance to
$345M, an increase from the previously provided guidance of
$340M, reflecting confidence in the business.
